Figure - available from: International Journal of Nanomedicine
This content is subject to copyright. Terms and conditions apply.
(A) Haematological analysis of mice after intravenously injected with Ca@H. (B) H&E staining of major organs excised from Ca@H treated-mice.
Source publication
Background
Therapeutic ultrasound (US) has been extensively explored for its inherent high tissue-penetrating capability and on-demand irradiation without radioactive damage. Although high-intensity focused ultrasound (HIFU) is evolved as such an outstanding US-based approach, its insufficient therapeutic effect and the high-intensity induced poten...
Citations
... Gao et al. constructed ca@h NPs with cores consisting of cacO 3 . cacO 3 is ph-responsive, stable in neutral environment and unstable in a weakly acidic tumor microenvironment where it decomposes to produce cO 2 (Gao et al., 2022). in addition, other familiar substances such as NahcO 3 , effervescent disintegrants etc. could also be used to provide cO 2 making the production process simpler and the cost lower, demonstrating its great possibilities for clinical application. ...
... additionally, the production of cO 2 can be coupled with the release of antitumor chemicals. in ca@h NPs, a typical acoustic-sensitive agent, hemaporphyrin-monommethyl ether (hMMe) is coupled to cacO 3 , in order to guide and promote tumor ablation through a series of combined therapeutic mechanisms and multi-mode effects (Gao et al., 2022). this successful combination shows its great application value in multi-therapy combined ablation. ...
High intensity focused ultrasound (HIFU) has demonstrated its safety, efficacy and noninvasiveness in the ablation of solid tumor. However, its further application is limited by its inherent deficiencies, such as postoperative recurrence caused by incomplete ablation and excessive intensity affecting surrounding healthy tissues. Recent research has indicated that the integration of nanomaterials with HIFU exhibits a promising synergistic effect in tumor ablation. The concurrent utilization of nanomaterials with HIFU can help overcome the limitations of HIFU by improving targeting and ablation efficiency, expanding operation area, increasing operation accuracy, enhancing stability and bio-safety during the process. It also provides a platform for multi-therapy and multi-mode imaging guidance. The present review comprehensively expounds upon the synergistic mechanism between nanomaterials and HIFU, summarizes the research progress of nanomaterials as cavitation nuclei and drug carriers in combination with HIFU for tumor ablation. Furthermore, this review highlights the potential for further exploration in the development of novel nanomaterials that enhance the synergistic effect with HIFU on tumor ablation.
... Flow cytometry analysis showed that Ce6 mediated the sonodynamic effect mainly through ROSinduced cell necrosis. A study on the possible mechanism of enhanced US of hematoporphyrin monomethyl ether (HMME) on the cytotoxicity of osteosarcoma has found that its cytotoxicity may be related to the increase of intracellular ROS and Ca (2+) , 33 whereas Bismuth et al., 34 in their study of the killing mechanism of safe low energy tumor cells by SDT, found that immediate cell lysis is closely linked to inertial cavitation, which is known to produce shear forces that signicantly disrupt cellular membranes. ...
Sonodynamic therapy (SDT) is an emerging approach for malignant tumor treatment, offering high precision, deep tissue penetration, and minimal side effects. The rapid advancements in nanotechnology, particularly in cancer treatment, have enhanced the efficacy and targeting specificity of SDT. Combining sonodynamic therapy with nanotechnology offers a promising direction for future cancer treatments. In this review, we first systematically discussed the anti-tumor mechanism of SDT and then summarized the common nanotechnology-related sonosensitizers and their recent applications. Subsequently, nanotechnology-related therapies derived using the SDT mechanism were elaborated. Finally, the role of nanomaterials in SDT combined therapy was also introduced.
... Moreover, Yue et al. demonstrate that SDT (1 MHz, 1.5 W/cm 2 ) with HP monomethyl ether eliminates the 4T1 murine breast cancer cell line [34]. As Quan-hong et al., Lv et al., and Gao et al. reported, when US was employed with HP, high toxicity and inhibitory effects were better than with US and HP [30,35,36]. In the present study, 5 mg/kg HP-MSN was injected 24 hours prior to US. ...
Purpose: According to the side effects of invasive cancer treatments, Sonodynamic Therapy (SDT) as a noninvasive method for breast adenocarcinoma was considered. Sonosensitizer agents’ encapsulation can improve the accumulation of these drugs in the tumor tissue and reduce treatment side effects. Hence, mice breast adenocarcinoma SDT with Hematoporphyrin (HP) and HP-encapsulated Mesoporous Silica Nanoparticles (HP-MSNs) was carried out.
Materials and Methods: Ninety-six female breast adenocarcinoma grafted Balb/C mice were randomly divided into 16 groups (n = 6): control, sham, HP, HP-MSN, Ultrasound (US), SDT+HP, and SDT+HP-MSN groups. Sonosensitizer agents were injected intraperitoneally (2.5 or 5 mg/kg, 0.2 ml) 24h before an US radiation (1MHz, 1 or 2 W/cm2, 60 sec). The tumor growth parameters were evaluated 30 days after SDT.
Results: The inhibition ratio was enhanced by 23, 18, 18, and 16% relative to the control group in HP-MSN (5 mg/kg), HP-MSN (2.5 mg/kg) HP (5 mg/kg) and US (2 W/cm2) groups, respectively, at 18 days after the injection time; whereas, the analysis of findings revealed an antitumor effect in SDT with HP-MSN groups. The Tumor Growth Inhibition (TGI) percentages were 45, 42, and 42% for the SDT (2 W/cm2) + HP-MSN (5 mg/kg), SDT (1 W/cm2) + HP-MSN (5 mg/kg), and SDT (2 W/cm2) + HP (2.5 mg/kg) groups, respectively, on the 18th day post-injection, and T2 and T5 times were higher than that of control and sham groups (P
... High-intensity focused ultrasound (HIFU), as a non-invasive means, has attracted more and more attention in clinical application [16][17][18]. The cavitation bubble is generated by the high negative pressure in the focal region of HIFU, and then oscillated and collapsed by HIFU. ...
In the luminol-O2 ECL system, O2 as an endogenous coreactant has the advantages of non-toxicity and stability. Improving the efficiency to generate radicals of O2 is a challenge currently. In this work, a strategy combining physical method - ultrasound and nanomaterial with unique physicochemical properties was designed to enhance the ECL signal of luminol-O2 system. Specifically, high-intensity focused ultrasound (HIFU) pretreatment as a non-invasive method could generate ROS (H2O2, O2•-, OH•, ¹O2) in situ, triggering and boosting the ECL signal of luminol. In addition, 1T/2H MoS2 with excellent catalytic activity could catalyze the H2O2 produced in situ, accelerate the oxidation of luminol and further enhance the ECL response. At the same time, combined with the catalytic hairpin assembly (CHA) reaction, the constructed ECL biosensing platform showed excellent performance for the detection of miRNA-155. The concentration range of 0.1 fM ∼ 1 nM with the detection limit as low as 0.057 fM were obtained. Furthermore, the ECL biosensor was also successfully applied to the determination of miRNA-155 in human serum samples. The established ECL sensing platform opens up a promising method for the detection of clinical biomarkers.
... Ultrasound stimuli-responsive nanoplatforms can therefore be a valuable tool for enhancing therapeutic agent accumulation in tumors with low EPR effects. For example, SDT-based nanoparticles capable of continuous production of CO 2 have been recently developed to accomplish ultrasound-mediated inertial cavitation (UIC) to augment ROS accumulation against cancer [390]. The in vitro and vivo results indicated that continuous UIC accelerated a massive generation of ROS, resulting in the improvement of SDT using a single nanoplatform. ...
Poor targeting of therapeutics leading to severe adverse effects on normal tissues is considered one of the obstacles in cancer therapy. To help overcome this, nanoscale drug delivery systems have provided an alternative avenue for improving the therapeutic potential of various agents and bioactive molecules through the enhanced permeability and retention (EPR) effect. Nanosystems with cancer-targeted ligands can achieve effective delivery to the tumor cells utilizing cell surface-specific receptors, the tumor vasculature and antigens with high accuracy and affinity. Additionally, stimuli-responsive nanoplatforms have also been considered as a promising and effective targeting strategy against tumors, as these nanoplatforms maintain their stealth feature under normal conditions, but upon homing in on cancerous lesions or their microenvironment, are responsive and release their cargoes. In this review, we comprehensively summarize the field of active targeting drug delivery systems and a number of stimuli-responsive release studies in the context of emerging nanoplatform development, and also discuss how this knowledge can contribute to further improvements in clinical practice.
... 124 Previous research has demonstrated that HMME can be utilized in PA imaging of malignancies. 125,126 At the same time, IR780 has a significant near-infrared absorption peak and generates high-intensity fluorescence in the 807-823 nm wavelength region, making it suitable for PA and FL imaging applications. [127][128][129] In vitro, PA imaging of the IHG@P solution determined an optimal excitation wavelength of 800 nm. ...
Sonodynamic therapy (SDT) is a rapidly developing non-surgical therapy that initiates sensitizers' catalytic reaction using ultrasound, showing great potential for cancer treatment due to its high safety and non-invasive nature. In addition, recent research has found that using different diagnostic and therapeutic methods in tandem can lead to better anticancer outcomes. Therefore, as essential components of SDT, sonosensitizers have been extensively explored to optimize their functions and integrate multiple medical fields. The review is based on five years of articles evaluating the combined use of SDT and imaging in treating cancer. By developing multifunctional sonosensitive particles that combine imaging and sonodynamic therapy, we have integrated diagnosis into the treatment of precision medicine applications, improving SDT cell uptake and antitumor efficacy utilizing different tumour models. This paper describes the imaging principle and the results of cellular and animal imaging of the multifunctional sonosensitizers. Efforts are made in this paper to provide data and design references for future SDT combined imaging research and clinical application development and to provide offer suggestions.
The use of nanocarriers for drug delivery has opened up exciting new possibilities in cancer treatment. Among them, calcium carbonate (CaCO3) nanocarriers have emerged as a promising platform due to their exceptional biocompatibility, biosafety, cost-effectiveness, wide availability, and pH-responsiveness. These nanocarriers can efficiently encapsulate a variety of small-molecule drugs, proteins, and nucleic acids, as well as co-encapsulate multiple drugs, providing targeted and sustained drug release with minimal side effects. However, the effectiveness of single-drug therapy using CaCO3 nanocarriers is limited by factors such as multidrug resistance, tumor metastasis, and recurrence. Combination therapy, which integrates multiple treatment modalities, offers a promising approach for tackling these challenges by enhancing efficacy, leveraging synergistic effects, optimizing therapy utilization, tailoring treatment approaches, reducing drug resistance, and minimizing side effects. CaCO3 nanocarriers can be employed for combination therapy by integrating drug therapy with photodynamic therapy, photothermal therapy, sonodynamic therapy, immunotherapy, radiation therapy, radiofrequency ablation therapy, and imaging. This review provides an overview of recent advancements in CaCO3 nanocarriers for drug delivery and combination therapy in cancer treatment over the past five years. Furthermore, insightful perspectives on future research directions and development of CaCO3 nanoparticles as nanocarriers in cancer treatment are discussed.
Calcium carbonate (CaCO3), a natural common inorganic material with good biocompatibility, low toxicity, pH sensitivity, and low cost, has a widespread use in the pharmaceutical and chemical industries. In recent years, an increasing number of CaCO3-based nano-drug delivery systems have been developed. CaCO3 as a drug carrier and the utilization of CaCO3 as an efficient Ca2+ and CO2 donor have played a critical role in tumor diagnosis and treatment and have been explored in increasing depth and breadth. Starting from the CaCO3-based nano-drug delivery system, this paper systematically reviews the preparation of CaCO3 nanoparticles and the mechanisms of CaCO3-based therapeutic effects in the internal and external tumor environments and summarizes the latest advances in the application of CaCO3-based nano-drug delivery systems in tumor therapy. In view of the good biocompatibility and in vivo therapeutic mechanisms, they are expected to become an advancing biomedicine in the field of tumor diagnosis and treatment.
Oxygen (O 2 ), nitric oxide (NO), carbon monoxide (CO), hydrogen sulfide (H 2 S), and hydrogen (H 2 ) with direct effects, and carbon dioxide (CO 2 ) with complementary effects on the condition of various diseases are known as therapeutic gases. The targeted delivery and in situ generation of these therapeutic gases with controllable release at the site of disease has attracted attention to avoid the risk of gas poisoning and improve their performance in treating various diseases such as cancer therapy, cardiovascular therapy, bone tissue engineering, and wound healing. Stimuli‐responsive gas‐generating sources and delivery systems based on biomaterials that enable on‐demand and controllable release are promising approaches for precise gas therapy. This work highlights current advances in the design and development of new approaches and systems to generate and deliver therapeutic gases at the site of disease with on‐demand release behavior. The performance of the delivered gases in various biomedical applications is then discussed.
